MPS Pharmaa Q4/FY26 Results Approved; Internal Auditor Reappointed

MPS Pharmaa's Board of Directors approved the standalone audited financial results for the quarter and financial year ended March 31, 2026. The board also re-appointed M/s Sanghi & Co., Chartered Accountants, as the Internal Auditor for FY 2026-27. The company reported a total income of ₹3.56 Lacs for Q4 FY26 and ₹6.3 Lacs for FY26, with a basic EPS of (₹0.19) for Q4 FY26 and (₹0.53) for FY26. The audit report included qualifications regarding investment valuation and stalled capital work in progress. The company is actively working to restart business operations and address outstanding Annual Listing Fees, which led to BSE suspending trading of its scrip.